Leptomeningeal Metastasis

  • Priscilla K. Brastianos
  • Charilaos H. Brastianos
  • April F. Eichler
Part of the Cancer Metastasis - Biology and Treatment book series (CMBT, volume 18)


Neoplastic meningitis is a common complication in cancer with a median survival on the order of weeks to months. Although there is no current standard of care, management of neoplastic meningitis typically requires a multidisciplinary approach that may include surgery, radiation and chemotherapy. Results from retrospective analyses have suggested that intrathecal chemotherapy improves patient outcomes in neoplastic meningitis. Chemotherapeutic agents commonly administered into the cerebrospinal fluid include methotrexate, thiotepa, cytosine arabinoside and liposomal cytarabine. Systemically administered agents are an alternative to intrathecal chemotherapy, and targeted agents are showing promise. Larger randomized controlled studies are needed to determine the optimal treatment regimen for this devastating manifestation of cancer.


Lumbar Puncture Leptomeningeal Metastasis Intrathecal Chemotherapy Intrathecal Methotrexate Neoplastic Meningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1.  1.
    Chamberlain MC, Johnston SK, Glantz MJ (2009) Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 66:74–78PubMedCrossRefGoogle Scholar
  2.  2.
    Fritsch K et al (2011) Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol Off J Eur Soc Med Oncol ESMO 22:2080–2085CrossRefGoogle Scholar
  3.  3.
    Kaplan JG et al (1990) Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9:225–229PubMedCrossRefGoogle Scholar
  4.  4.
    Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772PubMedCrossRefGoogle Scholar
  5.  5.
    Chamberlain MC, Johnston SK (2009) Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer 115:1941–1946PubMedCrossRefGoogle Scholar
  6.  6.
    Gauthier H et al (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol Off J Eur Soc Med Oncol ESMO 21:2183–2187CrossRefGoogle Scholar
  7.  7.
    Chamberlain MC, Corey-Bloom J (1991) Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 41:1765–1769PubMedCrossRefGoogle Scholar
  8.  8.
    Chamberlain MC (2008) Neoplastic meningitis. Oncologist 13:967–977PubMedCrossRefGoogle Scholar
  9.  9.
    Glass JP et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375PubMedCrossRefGoogle Scholar
  10. 10.
    Glantz MJ et al (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733–739PubMedCrossRefGoogle Scholar
  11. 11.
    Murray JJ et al (1983) Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 75:289–294PubMedCrossRefGoogle Scholar
  12. 12.
    Kang SJ et al (2010) Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis. J Clin Neurol 6:33–37PubMedCrossRefGoogle Scholar
  13. 13.
    Twijnstra A et al (1986) Cerebrospinal fluid carcinoembryonic antigen in patients with metastatic and nonmetastatic neurological diseases. Arch Neurol 43:269–272PubMedCrossRefGoogle Scholar
  14. 14.
    Bernstein WB et al (2008) Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 26:3281–3284CrossRefGoogle Scholar
  15. 15.
    Cone LA et al (2006) Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review. Surg Neurol 65:372–375, discussion 375–376PubMedCrossRefGoogle Scholar
  16. 16.
    Kosmas C et al (2005) Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer. Med Oncol 22:123–128PubMedCrossRefGoogle Scholar
  17. 17.
    van de Langerijt B et al (2006) CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 67:114–119PubMedCrossRefGoogle Scholar
  18. 18.
    Subira D et al (2012) Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro Oncol 14:43–52PubMedCrossRefGoogle Scholar
  19. 19.
    Chamberlain MC, Sandy AD, Press GA (1990) Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40:435–438PubMedCrossRefGoogle Scholar
  20. 20.
    Schumacher M, Orszagh M (1998) Imaging techniques in neoplastic meningiosis. J Neurooncol 38:111–120PubMedCrossRefGoogle Scholar
  21. 21.
    Freilich RJ, Krol G, DeAngelis LM (1995) Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38:51–57PubMedCrossRefGoogle Scholar
  22. 22.
    Glantz MJ et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:2919–2931PubMedCrossRefGoogle Scholar
  23. 23.
    Grossman SA et al (1982) Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 73:641–647PubMedCrossRefGoogle Scholar
  24. 24.
    Bruna J et al (2009) Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115:381–389PubMedCrossRefGoogle Scholar
  25. 25.
    Grossman SA et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561–569PubMedGoogle Scholar
  26. 26.
    Glantz MJ et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116PubMedGoogle Scholar
  27. 27.
    Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161–166PubMedCrossRefGoogle Scholar
  28. 28.
    Omuro AM et al (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64:1625–1627PubMedCrossRefGoogle Scholar
  29. 29.
    Lin N et al (2011) Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg 115:730–736PubMedCrossRefGoogle Scholar
  30. 30.
    Blasberg RG, Patlak C, Fenstermacher JD (1975) Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195:73–83PubMedGoogle Scholar
  31. 31.
    Boogerd W et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40:2726–2733PubMedCrossRefGoogle Scholar
  32. 32.
    Glantz MJ et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 5:3394–3402Google Scholar
  33. 33.
    Hitchins RN et al (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655–1662PubMedGoogle Scholar
  34. 34.
    Shapiro W et al (2006) A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24:1528CrossRefGoogle Scholar
  35. 35.
    Wang JJ, Pratt CB (1970) Intrathecal arabinosyl cytosine in meningeal leukemia. Cancer 25:531–534PubMedCrossRefGoogle Scholar
  36. 36.
    Herrlinger U et al (2009) Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 36:S25–S34PubMedCrossRefGoogle Scholar
  37. 37.
    Giannone L, Greco FA, Hainsworth JD (1986) Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4:68–73PubMedGoogle Scholar
  38. 38.
    Fleischhack G et al (2001) Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 84:1453–1459PubMedCrossRefGoogle Scholar
  39. 39.
    Groves MD et al (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10:208–215PubMedCrossRefGoogle Scholar
  40. 40.
    Brastianos PK et al (2012) The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. J Neurooncol 106:81–88PubMedCrossRefGoogle Scholar
  41. 41.
    Bigner DD et al (1995) Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1–14 F (ab′)2–a preliminary report. J Neurooncol 24:109–122PubMedCrossRefGoogle Scholar
  42. 42.
    Mego M et al (2011) Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast 20:478–480PubMedCrossRefGoogle Scholar
  43. 43.
    Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11:871–879PubMedCrossRefGoogle Scholar
  44. 44.
    Chamberlain MC (2003) Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 52:324–329, discussion 330PubMedCrossRefGoogle Scholar
  45. 45.
    Gangji D et al (1980) Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Eng J Med 303:19–21CrossRefGoogle Scholar
  46. 46.
    Tetef ML et al (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19–26PubMedCrossRefGoogle Scholar
  47. 47.
    Glantz MJ et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol Off J Am Soc Clin Oncol 16:1561–1567Google Scholar
  48. 48.
    Giglio P, Tremont-Lukats IW, Groves MD (2003) Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 65:167–172PubMedCrossRefGoogle Scholar
  49. 49.
    Rogers LR, Remer SE, Tejwani S (2004) Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol 6:63–64PubMedCrossRefGoogle Scholar
  50. 50.
    Tham YL et al (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRefGoogle Scholar
  51. 51.
    Lombardi G et al (2011) Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma. J Neurooncol 104:381–386PubMedCrossRefGoogle Scholar
  52. 52.
    Yi HG et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80–84PubMedCrossRefGoogle Scholar
  53. 53.
    Grommes C et al (2011) “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13:1364–1369PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Priscilla K. Brastianos
    • 1
    • 2
  • Charilaos H. Brastianos
    • 3
  • April F. Eichler
    • 4
  1. 1.Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Medical Oncology, Division of Hematology and Oncology, Yawkey 9EMassachusetts General Hospital Cancer Center, Harvard Medical SchoolBostonUSA
  2. 2.Department of Medical OncologyDana-Farber/Brigham and Women’s Cancer Center, Harvard Medical SchoolBostonUSA
  3. 3.Department of MedicineMcMaster UniversityHamiltonCanada
  4. 4.Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Division of Hematology and Oncology, Yawkey 9EMassachusetts General Hospital Cancer Center, Harvard Medical SchoolBostonUSA

Personalised recommendations